Estrella Immunopharma (Estrella Immunopharma) Asset Impairment Charge : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Asset Impairment Charge?

Estrella Immunopharma's Asset Impairment Charge for the three months ended in Mar. 2024 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Estrella Immunopharma Asset Impairment Charge Historical Data

The historical data trend for Estrella Immunopharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Asset Impairment Charge Chart

Estrella Immunopharma Annual Data

Trend

Jun21

Asset Impairment Charge

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial					-	-	-	-	-

Estrella Immunopharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Estrella Immunopharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines